Northfield’s BLA for red blood cell drug granted FDA priority review
In addition, FDA has designated the submission for priority review, with a review goal date of April 30, 2009. Northfield had previously submitted the biologics license application (BLA)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.